Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis

Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation

(2012) Takeshi Yamashita et al.   CIRCULATION JOURNAL

Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation

(2012) Masatsugu Hori et al.   CIRCULATION JOURNAL

Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials

(2012) Koon-Hou Mak   BMJ Open

Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial Fibrillation

(2011) Satoshi Ogawa et al.   CIRCULATION JOURNAL

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPEAN HEART JOURNAL

Minimizing Bias in Randomized Trials

(2010) Bruce M. Psaty et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Newly Identified Events in the RE-LY Trial

(2010) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

(2010) Stuart Connolly et al.   THROMBOSIS AND HAEMOSTASIS

Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation

(2010) Hui-Kyung Jeon et al.   THROMBOSIS AND HAEMOSTASIS

The new oral anticoagulants

(2009) D. Garcia et al.   BLOOD

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists

(2009) G. Y.H. Lip et al.   EUROPEAN HEART JOURNAL

Open-label trials and drug registration: a European regulator’s view

(2009) M. CASTEELS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antithrombotic Therapy in Atrial Fibrillation

(2008) Daniel E. Singer et al.   CHEST

Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants

(2008) H. R. BÜLLER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

(2008) Lesley Wood et al.   BMJ-British Medical Journal